blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2753317

EP2753317 - TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.01.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  24.01.2020
FormerGrant of patent is intended
Status updated on  17.09.2019
FormerExamination is in progress
Status updated on  03.09.2019
FormerGrant of patent is intended
Status updated on  20.08.2019
FormerExamination is in progress
Status updated on  05.07.2019
FormerGrant of patent is intended
Status updated on  21.02.2019
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
CuRNA, Inc.
4400 Biscayne Boulevard
Miami, FL 33137 / US
[2014/29]
Inventor(s)01 / COLLARD, Joseph
1004 Brooks Lane
Delray Beach, Florida 33483 / US
02 / KHORKOVA SHERMAN, Olga
18288 SE Heritage Drive
Tequesta, Florida 33469 / US
03 / HSIAO, Jane H.
4400 Biscayne Boulevard
Miami, Florida 33137 / US
 [2014/29]
Representative(s)Gregson, Anna Louise, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2020/09]Gregson, Anna Louise, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London
SE1 9SG / GB
Former [2014/29]Evenson, Jane Harriet, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Application number, filing date12829528.428.08.2012
[2020/09]
WO2012US52685
Priority number, dateUS201161531361P06.09.2011         Original published format: US 201161531361 P
[2014/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013036403
Date:14.03.2013
Language:EN
[2013/11]
Type: A1 Application with search report 
No.:EP2753317
Date:16.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 14.03.2013 takes the place of the publication of the European patent application.
[2014/29]
Type: B1 Patent specification 
No.:EP2753317
Date:26.02.2020
Language:EN
[2020/09]
Search report(s)International search report - published on:US14.03.2013
(Supplementary) European search report - dispatched on:EP06.03.2015
ClassificationIPC:A61K31/00, A61K38/00, A61K31/135
[2015/15]
CPC:
A61K31/135 (EP,US); A61K31/436 (US); A61K31/165 (EP,US);
A61K31/365 (EP,US); A61K31/41 (EP,US); A61K31/4245 (EP,US);
A61K31/4409 (EP,US); A61K31/4422 (EP,US); A61K31/4439 (EP,US);
A61K31/4545 (EP,US); A61K31/495 (EP,US); A61K31/496 (EP,US);
A61K31/4985 (EP,US); A61K31/519 (EP,US); A61K31/5375 (EP,US);
A61K31/5513 (EP,US); A61K31/58 (EP,US); A61K31/64 (EP,US);
A61K31/7048 (EP,US); A61P1/04 (EP); A61P13/08 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P15/10 (EP);
A61P25/00 (EP); A61P25/06 (EP); A61P25/08 (EP);
A61P9/00 (EP); A61P9/04 (EP); A61P9/12 (EP);
Y02A50/30 (EP,US) (-)
Former IPC [2014/29]A61K31/00, A61K38/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/29]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT ALPHA-UNTEREINHEITEN VON NATRIUMKANÄLEN, SPANNUNGSGESTEUERT (SCNXA) MIT KLEINEN MOLEKÜLEN[2014/29]
English:TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES[2014/29]
French:TRAITEMENT DE MALADIES LIÉES À DES SOUS-UNITÉS ALPHA DE CANAUX SODIQUES VOLTAGE-DÉPENDANTS (SCNXA) AVEC DE PETITES MOLÉCULES[2014/29]
Entry into regional phase27.03.2014National basic fee paid 
27.03.2014Search fee paid 
27.03.2014Designation fee(s) paid 
27.03.2014Examination fee paid 
Examination procedure27.03.2014Examination requested  [2014/29]
02.10.2015Amendment by applicant (claims and/or description)
15.06.2016Despatch of a communication from the examining division (Time limit: M06)
12.12.2016Reply to a communication from the examining division
21.06.2017Despatch of a communication from the examining division (Time limit: M06)
21.12.2017Reply to a communication from the examining division
29.01.2018Despatch of a communication from the examining division (Time limit: M06)
26.07.2018Reply to a communication from the examining division
08.08.2018Despatch of a communication from the examining division (Time limit: M04)
14.12.2018Reply to a communication from the examining division
22.02.2019Communication of intention to grant the patent
01.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.09.2019Communication of intention to grant the patent
16.01.2020Fee for grant paid
16.01.2020Fee for publishing/printing paid
16.01.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.06.2016
Opposition(s)27.11.2020No opposition filed within time limit [2021/05]
Fees paidRenewal fee
27.08.2014Renewal fee patent year 03
27.08.2015Renewal fee patent year 04
29.08.2016Renewal fee patent year 05
28.08.2017Renewal fee patent year 06
27.08.2018Renewal fee patent year 07
27.08.2019Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.08.2012
AL26.02.2020
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MK26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
LU28.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
[2022/31]
Former [2022/30]HU28.08.2012
AL26.02.2020
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
LU28.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2022/27]HU28.08.2012
AT26.02.2020
CY26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
MT26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
LU28.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2022/26]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
TR26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
LU28.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/36]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
LU28.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/20]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
LU28.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/18]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
MC26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2021/10]AT26.02.2020
CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
IT26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
PL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SI26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/50]CZ26.02.2020
DK26.02.2020
EE26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/49]CZ26.02.2020
DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SK26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/48]DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RO26.02.2020
RS26.02.2020
SE26.02.2020
SM26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
PT19.07.2020
Former [2020/47]DK26.02.2020
ES26.02.2020
FI26.02.2020
HR26.02.2020
LT26.02.2020
LV26.02.2020
NL26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/45]FI26.02.2020
HR26.02.2020
LV26.02.2020
NL26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/40]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
IS26.06.2020
Former [2020/39]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
BG26.05.2020
NO26.05.2020
GR27.05.2020
Former [2020/38]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
NO26.05.2020
GR27.05.2020
Former [2020/37]FI26.02.2020
HR26.02.2020
LV26.02.2020
RS26.02.2020
SE26.02.2020
NO26.05.2020
Former [2020/35]FI26.02.2020
NO26.05.2020
Documents cited:Search[X]WO0138564  (UNIV MCGILL [CA], et al) [X] 1-4,6-10,13 * claim 12 and Examples *;
 [X]US2003055036  (WERNER PETER [US], et al) [X] 1-4,6,11,12 * claims 1, 3, 5 *;
 [X]  - S MOUSSAOUI, "The Antioxidant Ebselen Prevents Neurotoxicity and Clinical Symptoms in a Primate Model of Parkinson's Disease", EXPERIMENTAL NEUROLOGY, (20001201), vol. 166, no. 2, doi:10.1006/exnr.2000.7516, ISSN 0014-4886, pages 235 - 245, XP055171445 [X] 1-4,6,11,12,15 * the whole document *

DOI:   http://dx.doi.org/10.1006/exnr.2000.7516
 [X]  - JW WARD, "Pinacidil monotherapy for hypertension.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (19840801), vol. 18, no. 2, doi:10.1111/j.1365-2125.1984.tb02456.x, ISSN 0306-5251, pages 223 - 225, XP055171453 [X] 1-3,5,6,12,15 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1365-2125.1984.tb02456.x
International search[X]  - YAMAMOTO ET AL., "Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells", J. NEUROCHEM., (199704), vol. 68, no. 4, pages 1655 - 1662, XP055146846
 [X]  - DUFF ET AL., "Class I and IV Antiarrhythmic Drugs and Cytosolic Calcium Regulate mRNA Encoding the Sodium Channel alpha Subunit in Rat Cardiac Muscle", MOL. PHARMACOL., (199210), vol. 42, no. 4, pages 570 - 574, XP008173646
 [A]  - CATTERALL ET AL., "International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels", PHARMACOL. REV., (200512), vol. 57, no. 4, pages 397 - 409, XP055146853

DOI:   http://dx.doi.org/10.1124/pr.57.4.4
ExaminationWO2011163499
    - FUJIWARA ET AL, "Clinical spectrum of mutations in SCN1A gene: Severe myoclonic epilepsy in infancy and related epilepsies", EPILEPSY RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 70, doi:10.1016/J.EPLEPSYRES.2006.01.019, ISSN 0920-1211, (20060801), pages 223 - 230, (20060801), XP025114867

DOI:   http://dx.doi.org/10.1016/j.eplepsyres.2006.01.019
    - SCHEFFER I E ET AL, "Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?", BRAIN AND DEVELOPMENT, AMSTERDAM, NL, vol. 31, no. 5, doi:10.1016/J.BRAINDEV.2009.01.001, ISSN 0387-7604, (20090501), pages 394 - 400, (20090208), XP026053272

DOI:   http://dx.doi.org/10.1016/j.braindev.2009.01.001
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.